MustGrow Biologics Reports Record $2.8M Q2 Revenue Driven by US TerraSante Sales

MustGrow Biologics Corp. reported record revenue of $2.8 million for the second quarter of 2025, a significant increase from zero revenue in the same period of 2024, driven largely by strong sales of its TerraSante biofertility product in the U.S. The company achieved a gross profit margin of 20.9%, up from 14.3% in the first quarter, with TerraSante sales tripling compared to 2024. MustGrow sold out its U.S. TerraSante inventory during Q2 and is ramping up production to meet increasing demand. Despite recording a net loss of $1.1 million, the company remains optimistic about growth, especially through its NexusBioAg division in Canada, which experiences stronger sales in Q1 and Q4. MustGrow held $1.8 million in cash and $1.8 million in inventory as of June 30, 2025, and continues to focus on expanding its regenerative agriculture solutions and intellectual property portfolio. CEO Corey Giasson emphasized the company’s commitment to meeting demand and finishing the year with strong Q4 results.